MYC and neuroendocrine carcinoma: This is different from Quarfloxin (CX‐3453), a specifically designed inhibitor to induce apoptosis by reducing c‐Myc mRNA in neuroendocrine carcinoma.[50] However, we observed that CU27 may sensitize cancer cells to chemotherapeutics, especially current first‐class drug sorafenib in vitro and in vivo.